Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations

BACKGROUND: Evidence from clinical trials shows that newer second-line diabetes medications—glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is)—have cardio-renal protective effects in addition to their glucose-lowering properties. Despite stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogunsanmi, Deborah O, Harrison, Austin T, Pakker, Avinash R, Kovesdy, Csaba P, Bailey, James E, Surbhi, Satya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Social and Racial Inequities in Medication Use
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387916/
https://www.ncbi.nlm.nih.gov/pubmed/37276038
http://dx.doi.org/10.18553/jmcp.2023.29.6.699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387916/
https://www.ncbi.nlm.nih.gov/pubmed/37276038
http://dx.doi.org/10.18553/jmcp.2023.29.6.699

Ejemplares similares